The metabolic syndrome and cancer: Is the metabolic syndrome useful for predicting cancer risk above and beyond its individual components?
J Harding, M Sooriyakumaran, KJ Anstey, R Adams, B Balkau, T Briffa, TME Davis, WA Davis, A Dobson, GG Giles, J Grant, M Knuiman, M Luszcz, P Mitchell, JA Pasco, C Reid, D Simmons, L Simons, A Tonkin, M Woodward Show all
DIABETES & METABOLISM | MASSON EDITEUR | Published : 2015
AIMS: The metabolic syndrome (MetS) is a risk factor for cancer. However, it is not known if the MetS confers a greater cancer risk than the sum of its individual components, which components drive the association, or if the MetS predicts future cancer risk. MATERIALS AND METHODS: We linked 20,648 participants from the Australian and New Zealand Diabetes and Cancer Collaboration with complete data on the MetS to national cancer registries and used Cox proportional hazards models to estimate associations of the MetS, the number of positive MetS components, and each of the five MetS components separately with the risk for overall, colorectal, prostate and breast cancer. Hazard ratios (HR) and ..View full abstract
Awarded by National Health and Medical Research Council (NHMRC)
this work is funded by a National Health and Medical Research Council (NHMRC grant APP1002663), Australian Government Department of Health. The work is supported, in part, by the Victorian Operational Infrastructure Scheme. JLH is supported by a Monash University Australian Postgraduate Award and a Baker IDI Bright Sparks scholarship, JES is supported by National Health and Medical Research Council Senior Research Fellowship (ID 526609), DJM is supported by a Victorian Cancer Agency Public Health Fellowship. Funding sources for individual studies can be found in baseline papers listed in the reference list.